Skip to content
Screener

GeneDx Holdings WGS Q2 2025 earnings

Reported July 29, 2025 · Before market open

Revenue$102.7MBeat by $4.1M
EPS$0.50Beat by $0.40
Revenue estimate$98.6M
EPS estimate$0.10

Next report

Oct 27, 2026 (in a month)
Revenue estimate$123.0M
EPS estimate$0.07

Financials

Q2 2025

Income statement

See full
Revenue$102.7M+45.6%
Gross profit$70.9M+65.1%
Operating income$9.0M+185%
Net income$10.8M+137%
EPS (diluted)$0.36+133%

Balance sheet

See full
Cash & equivalents$75.1M+31.6%
Total debt$52.9M-0.7%
Total equity$277.1M+42.8%
Total assets$463.9M+19.2%

Cash flow

See full
Operating cash flow$10.4M+331%
CapEx$2.4M+75.2%
Free cash flow$8.1M+237%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.59B+279%
Enterprise value$2.57B+278%
P/S7.2×+4.4×

Profitability

See full
Gross margin67.2%+11.2pp
FCF margin0.2%+0.1pp

Returns & leverage

See full
Debt / equity0.2×-0.1×
Current ratio2.9×+0.5×

FAQ

When did GeneDx Holdings report Q2 2025 earnings?
GeneDx Holdings (WGS) reported Q2 2025 earnings on July 29, 2025 before market open.
What were GeneDx Holdings's Q2 2025 revenue and EPS?
GeneDx Holdings reported revenue of $102.7M and eps of $0.50 for Q2 2025.
Did GeneDx Holdings beat estimates in Q2 2025?
Revenue beat the consensus estimate of $98.6M by $4.1M. EPS beat the consensus estimate of $0.10 by $0.40.
How did GeneDx Holdings's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 45.6% from $70.5M a year earlier.
Where can I find GeneDx Holdings's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001818331-25-000105) and the 10-Q periodic report (0001818331-25-000108) directly on SEC EDGAR. The filing index links above go to sec.gov.